Abstract:Objective To study if the protective effect of dexmedetomidine on the pyohemia-associated delirium is through the cholinergic anti-inflammatory pathway.Methods Sixty male adult C57 mice were randomly divided into five groups (n=12 each): saline group (group C),dexmedetomidine (DEX) alone group (group DEX),endotoxemia (LPS) group (group LPS),dexmedetomidine protection group (group LPS+DEX) and alpha-bungarotoxin (α-BGT) group (group α-BGT).Each group were assigned to two subunits (n=6 each),mice in subunit one were sacrificed after examining the open field test,mice in subunit two were sacrificed after testing the novel object recognition.The level of inflammatory factors were measured by enzyme-linked immune sorbent assay (ELISA).The ultrastructure changes of the hippocampus in mice were observed by transmission electron microscopy.Results Compared with group C,there are no significant differences in group DEX.Dexmedetomidine significantly attenuated the delirious syndrome after LPS induced endotoxemia,however,the effect of dexmedetomidine disappeared in group α-BGT,and the syndrome of cognitive dysfunction in LPS group were more severe than that in group α-BGT.(1) The open field test show that there are no significant differences each group with that before model establishment;after the models were established 24 h,compared with group C,group LPS show that the abilities of cognition to new environment、learning and memory were decreasing,the tension is increasing.preemptive administration of dexmedetomidine significantly attenuated the delirious syndrome after LPS induced endotoxemia;however,preemptive administration of dexmedetomidine failed to control the delirious syndrome in group α-BGT.(2) The novel object recognition testshow that compared to group C,the ability of exploring the novel object is decreasing;preemptive administration of dexmedetomidine significantly improve the exploration ability,however,preemptive administration of dexmedetomidine failed to control the delirious syndrome in group α-BGT.(3) The results of ELISA show that: Compared with group C,the concentrations of tumor necrosis factor-α (TNF-α) and interleukin (IL)-1β in serum and Hippocampus were all increased in LPS groups[Serum (ng/L) TNF-α: 794.80±93.99 vs.23.60±3.03,IL-1β: 148.49±24.80 vs.64.55±5.13,Hippocampus (pg/mg·prot) TNF-α: 176.14±11.25 vs.6.71±0.49,IL-1β: 50.61±5.86 vs.16.73±1.15,P=0.000],compared with group LPS,the concentrations were all significantly decreased in group LPS+DEX[Serum (ng/L) TNF-α: 184.44±26.58 vs.794.80±93.99,IL-1β: 77.43±10.75 vs.148.49±24.80,Hippocampus (pg/mg·prot) TNF-α: 64.83±13.09 vs.176.14±11.25,IL-1β: 17.97±2.26 vs.50.61±5.86,P=0.000].However,α-BGT can reverse the protective effect[Serum (ng/L): TNF-α: 812.31±86.25 vs.184.44±26.58,IL-1β: 156.42±17.94 vs.77.43±10.75,Hippocampus (pg/mg·prot) TNF-α: 181.94±8.69 vs.64.83±13.09,IL-1β: 52.10±5.59 vs.17.97±2.26,P=0.000].TEM shown that the histopathological damage of hippocampus tissue in group LPS and α-BGT were heavier,which in group LPS+DEX was reversed partially.Conclusion Central alpha-2 agonist dexmedetomidine attenuates sepsis-associated delirium syndrome likely through activating cholinergic anti-inflammatory pathway and inhibiting the inflammatory responses in serum and brain.

The Role of Spleen in the Treatment of Experimental Lipopolysaccharide-Induced Sepsis with Dexmedetomidine

Dexmedetomidine Attenuates Inflammatory Reaction in the Lung Tissues of Septic Mice by Activating Cholinergic Anti-Inflammatory Pathway

Dexmedetomidine Attenuates Lipopolysaccharide-Induced Sympathetic Activation and Sepsis via Suppressing Superoxide Signaling in Paraventricular Nucleus

The role of the vagus nerve on dexmedetomidine promoting survival and lung protection in a sepsis model in rats

Dexmedetomidine Attenuates Lipopolysaccharide-Induced Liver Oxidative Stress and Cell Apoptosis in Rats by Increasing GSK-3β/MKP-1/Nrf2 Pathway Activity Via the Α2 Adrenergic Receptor.

Dexmedetomidine Prevents Septic Myocardial Dysfunction in Rats Via Activation of Α7nachr and PI3K/Akt- Mediated Autophagy.

Dexmedetomidine Attenuates Oxidative/nitrative Stress in Lung Tissues of Septic Mice Partly Via Activating Heme Oxygenase-1.

Dexmedetomidine Controls Systemic Cytokine Levels Through the Cholinergic Anti-inflammatory Pathway

The protective effect of dexmedetomidine on the liver injury in sepsis through inhibition of necroptosis

Dexmedetomidine Ameliorates LPS Induced Acute Lung Injury Via GSK-3β/STAT3-NF-κB Signaling Pathway in Rats

Posttreatment with Dexmedetomidine Aggravates LPS-induced Myocardial Dysfunction Partly Via Activating Cardiac Endothelial Α2a-Ar in Mice.

Dexmedetomidine attenuates sepsis-associated acute lung injury by regulating macrophage efferocytosis through the ROS/ADAM10/AXL pathway

Dexmedetomidine alleviates cognitive impairment by reducing blood-brain barrier interruption and neuroinflammation via regulating Th1/Th2/Th17 polarization in an experimental sepsis model of mice

Dexmedetomidine Attenuates Lipopolysaccharide-Induced Inflammation Through Macrophageal IL-10 Expression Following Α7 Nachr Activation

Dexmedetomidine attenuates pyohemia-associated delirium in mice through the cholinergic anti-inflammatory pathway

Dexmedetomidine Ameliorates Lipopolysaccharide-Induced Acute Kidney Injury In Rats By Inhibiting Inflammation And Oxidative Stress Via The Gsk-3 Beta/Nrf2 Signaling Pathway

Dexmedetomidine alleviates lipopolysaccharide-induced acute kidney injury by inhibiting the NLRP3 inflammasome activation via regulating the TLR4/NOX4/NF-κB pathway.

Dexmedetomidine inhibits astrocyte pyroptosis and subsequently protects the brain in in vitro and in vivo models of sepsis

Effects of Dexmedetomidine on Survival Rate, IL-6 and IL-10 of Rats with Sepsis

Mechanisms of Renal-Splenic Axis Involvement in Acute Kidney Injury Mediated by the α7nAChR-NF-κB Signaling Pathway

Dexmedetomidine May Produce Extra Protective Effects on Sepsis-induced Diaphragm Injury.